<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511990</url>
  </required_header>
  <id_info>
    <org_study_id>MCA-0885</org_study_id>
    <nct_id>NCT02511990</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074</brief_title>
  <official_title>A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 Monoclonal Antibody in HIV-infected and HIV-uninfected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 clinical trial to evaluate the safety, pharmacokinetics and the
      antiretroviral effects of the highly neutralizing anti-HIV-1 monoclonal antibody 10-1074 in
      HIV-infected and HIV-uninfected individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In preclinical studies carried out in humanized mice and non-human primates, 10-1074 alone or
      in combination with other neutralizing antibodies led to protection from HIV or simian/human
      immunodeficiency virus (SHIV) infection and also to sustained suppression of HIV plasma
      viremia. The aims of this protocol are to evaluate the safety, tolerability and
      pharmacokinetics profile of 10-1074 in both HIV-infected and HIV-uninfected individuals, and
      its antiretroviral activity in HIV-infected individuals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>24 weeks after 10-1074 administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum peak concentration of 10-1074, measured in micrograms per ml</measure>
    <time_frame>24 hours after 10-1074 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum half-life of 10-1074 expressed in days</measure>
    <time_frame>24 Weeks after 10-1074 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV-1 RNA levels measured in copies/ml</measure>
    <time_frame>2 weeks after 10-1074 administration</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals Off ART, HIV-1 viral load &lt; 100,000 copies/ml or On ART, HIV-1 viral load &lt; 500 copies/ml
3 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals Off ART, HIV-1 viral load &lt; 100,000 copies/ml or On ART, HIV-1 viral load &lt; 500 copies/ml
10 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals Off ART, HIV-1 viral load &lt; 100,000 copies/ml or On ART, HIV-1 viral load &lt; 500 copies/ml
30 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals Off ART, HIV-1 viral load &lt; 100,000 copies/ml
30 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals
3 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals
10 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals
30 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals
30 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3 mg/kg, single dose IV administration of 10-1074</intervention_name>
    <description>3 mg/kg, single dose IV administration of 10-1074</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10 mg/kg, single dose IV administration of 10-1074</intervention_name>
    <description>10 mg/kg, single dose IV administration of 10-1074</description>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_label>Group 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>30 mg/kg, single dose IV administration of 10-1074</intervention_name>
    <description>30 mg/kg, single dose IV administration of 10-1074</description>
    <arm_group_label>Group 1C</arm_group_label>
    <arm_group_label>Group 1D</arm_group_label>
    <arm_group_label>Group 2C</arm_group_label>
    <arm_group_label>Group 2D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 1 (HIV-infected)

          -  Males and females, age 18 to 65

          -  HIV-1 infection confirmed by two independent assays.

          -  Group (1A-1C): HIV-infected individuals off ART for at least 8 weeks with HIV-1 plasma
             RNA levels &lt; 100,000 copies/ml by standard assays, or on ART with HIV-1 plasma RNA
             levels &lt; 500 copies/ml. HIV-1 RNA levels should be measured on 2 occasions, at least 1
             week apart and one measurement must be performed within 49 days prior to enrollment.

          -  Group (1D): HIV-infected individuals off ART for at least 8 weeks with HIV-1 plasma
             RNA levels &lt; 100,000 copies/ml by standard assays, measured on 2 occasions, at least 1
             week apart. At least one measurement must be performed within 49 days prior to
             enrollment.

          -  Current CD4 count &gt; 300 cells/μl.

          -  If sexually active male or female, and participating in sexual activity that could
             lead to pregnancy, agrees to use two effective methods of contraception from 10 days
             prior to the 10-1074 infusion until the end of the study.

        Group 2 (HIV-uninfected):

          -  Males and females, age 18 to 65.

          -  Amenable to HIV risk reduction counseling and agrees to maintain behavior consistent
             with low risk of HIV exposure.

          -  If sexually active male or female, and participating in sexual activity that could
             lead to pregnancy, agrees to use two effective methods of contraception throughout the
             study period, as described for the HIV-infected groups above.

        Exclusion Criteria:

        Group 1 (HIV-infected):

          -  Have a history of AIDS-defining illness within 1 year prior to enrollment.

          -  History of systemic corticosteroids, immunosuppressive anti-cancer, or other
             medications considered significant by the trial physician within the last 6 months.

          -  Any clinically significant acute or chronic medical condition other than HIV
             infection, that in the opinion of the investigator would preclude participation.

          -  Chronic Hepatitis B or Hepatitis C infection.

          -  Laboratory abnormalities in the parameters listed below:

        Absolute neutrophil count ≤ 1,000; Hemoglobin ≤10 gm/dL; Platelet count ≤100,000; ALT ≥ 2.0
        x ULN; AST ≥ 2.0 x ULN; Total bilirubin ≥ 1.25 x ULN; Creatinine ≥ 1.1 x ULN; Coagulation
        parameters (PT, PTT or INR) ≥ 1.25 x ULN.

          -  Pregnancy or lactation.

          -  Any vaccination within 14 days prior to 10-1074 administration.

          -  History of severe reaction to a vaccine or drug infusion or history of severe allergic
             reactions.

          -  Participation in another clinical study of an investigational product currently or
             within past 12 weeks, or expected participation during this study.

        Group 2 (HIV-uninfected):

          -  Confirmed HIV-1 or HIV-2 infection.

          -  History of immunodeficiency or autoimmune disease; use of systemic corticosteroids,
             immunosuppressive anti-cancer, or other medications considered significant by the
             trial physician within the last 6 months.

          -  Any clinically significant acute or chronic medical condition (such as autoimmune
             diseases) that in the opinion of the investigator would preclude participation.

          -  Within the 12 months prior to enrollment, the volunteer has a history of sexually
             transmitted infection.

          -  Chronic Hepatitis B or Hepatitis C infection.

          -  Laboratory abnormalities in the parameters listed:

        Absolute neutrophil count ≤ 1,500; Hemoglobin ≤ 12 gm/dL if female; ≤ 13.5 gm/dL if male;
        Platelet count ≤ 140,000; Alanine transaminase (ALT) ≥ 1.25 x upper limit of normal (ULN);
        aspartate transaminase (AST) ≥ 1.25 x ULN; Total bilirubin ≥ 1.25 x ULN; Creatinine ≥ 1.1 x
        ULN; Coagulation parameters (prothrombin time - PT, partial thromboplastin time - PTT or
        INR) ≥ 1.25 x ULN.

          -  Pregnancy or lactation.

          -  Any vaccination within 14 days prior to 10-1074 administration.

          -  Receipt of any experimental HIV vaccine in the past.

          -  History of severe reaction to a vaccine or drug infusion or history of severe allergic
             reactions.

          -  Participation in another clinical study of an investigational product currently or
             within past 12 weeks, or expected participation during this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Caskey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>10-1074</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

